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Ketamine is a broadly used anaesthetic for analgosedation. Accumulating clinical evidence shows that ketamine causes pulmonary
edema with unknown mechanisms. We measured the eﬀects of ketamine on alveolar ﬂuid clearance in human lung lobes ex
vivo. Our results showed that intratracheal instillation of ketamine markedly decreased the reabsorption of 5% bovine serum
albumin instillate. In the presence of amiloride (a speciﬁc ENaC blocker), ﬂuid resolution was not further decreased, suggesting
that ketamine could decrease amiloride-sensitive fraction of AFC associated with ENaC. Moreover, we measured the regulation of
amiloride-sensitive currents by ketamine in A549 cells using whole-cell patch clamp mode. Our results suggested that ketamine
decreased amiloride-sensitive Na+ currents (ENaC activity) in a dose-dependent fashion. These data demonstrate that reduction
in lung ENaC activity and lung ﬂuid clearance following administration of ketamine may be the crucial step of the pathogenesis of
resultant pulmonary edema.
1.Introduction
Ketamine is a broadly used anaesthetic for analgosedation,
especially during sepsis and cardiovascular instability. Intra-
operative pulmonary edema has been reported worldwide
following intramuscular or intravenous ketamine admin-
istration [1–5]. Pulmonary edema is the abnormal ﬂuid
accumulation in the interstitial or alveolar spaces of the lung.
Active Na+ reabsorption across lung epithelia requires the
sequential coordination of the entry of Na+ ions through
Na+-selective, amiloride-sensitive epithelial Na+ channels
(ENaC) located at the apical membranes, followed by the
extrusion across the basolateral membranes by the energy-
consuming Na+-K+-ATPase. The entry of Na+ ions through
apical membranes is thought to be the critical step in this
process [6–9].
Traditional teaching is that pulmonary edema occurring
in patients tends to be cardiac in aetiology, usually with
left heart dysfunction which caused back pressure across the
pulmonary system, and led to extravasation of ﬂuid into the
alveolar space. In patients undergoing anaesthesia, higher
afterload as in neurogenic causes or other noncardiogenic
pulmonary edema are also encountered [1–3]. Ketamine can
clinically induce lung edema as well as increase pulmonary
vascular permeability and arterial pressure. However, the
eﬀects of ketamine on alveolar Na+ transport in human
lungs are not known. Alveolar ﬂuid clearance (AFC) has
been widely used in understanding lung ﬂuid balance, not
only under normal but also pathologic conditions, for
example, in acute lung injury (ALI) and acute respiratory
distress syndrome (ARDS). Stimulation of AFC accelerates
the resolution of pulmonary edema, which beneﬁts gas
exchange across the alveolar epithelium [10]. In contrast,
impairment of AFC is often related with worsened survival
in ALI and ARDS patients [11, 12], which leads to the
development of pulmonary edema [13]. In this paper, we2 Journal of Biomedicine and Biotechnology
evaluated whether AFC of ﬂuid-instilled human lung lobes
is impaired when ketamine is administered into the alveolar
space ex vivo, aiming to ﬁnd the role of ketamine in lung
epithelial ﬂuid transport.
As we know, lung alveolar tissue from human is not
readily available, and the use of isolated alveolar cells from
other species has inherent disadvantages due to species
variation. Other problems with acutely isolating cells are
possible contamination by microorganisms and damage
to the channel proteins by the digestive processes that
is necessary for dissociation. A549 cell line is originated
from a human alveolar cell carcinoma and possesses many
characteristics of Type II alveolar cells [14], which can
synthesize phospholipids, consistent with the well-described
function of Type II alveolar cells-synthesis of pulmonary
surfactant [15, 16]. Here, we used whole-cell patch clamp
technique to identify the eﬀects of ketamine on vectorial Na+
transport in A549 cells in vitro. Our results demonstrate that
ketamine can inhibit ENaC and decrease ENaC-associated
ﬂuid clearance across the distal lung epithelium.
2.Methods and Materials
2.1. Ex Vivo Human Lung Study. Human lungs were ob-
tained from patients who underwent pneumonectomy for
lung cancer (Department of Thoracic surgery, First Aﬃliated
Hospital of China Medical University, Shenyang, China).
This study was approved by the responsible ethics committee
and by written informed patient consent. There were no
pulmonary ﬁbrosis or emphysema as assessed by preop-
erative computed tomograms. The lung samples excised
from patients exposed to stimulants were excluded for our
study. Preoperative pulmonary function tests were normal
in all patients (see Table 1). The surgical procedure and lung
segment chosen were done as described previously [17, 18].
Brieﬂy, immediately after removal of the lung, we occluded
the segmental bronchus with a 10-Fr. balloon catheter and
then chose a segment furthest away from the tumor. A
warmednormalsalinesolution(20mL,37◦C)containing5%
bovine serum albumin with or without amiloride (1mM)
or ketamine (racemate, 100μM) was instilled into the distal
air spaces through the catheter. We understand that iv
perfusion of ketamine will mimic the clinical circumstance.
Unfortunately, ketamine cannot be applied via blood vessels
of excised human lung lobes due to incompleted pulmonary
circulation. Instead, the advantage of intratracheal delivery
is that we are able to examine the direct eﬀects of ketamine
on alveolar epithelial function. After instillation, the lung
segments were inﬂated with 100% oxygen at an airway
pressure of 7cm H2O. The temperature in this experiment
was kept 37◦C controlled by a waterbath. Alveolar ﬂuid was
aspirated 60min later and then was centrifuged at 6500 rpm
for 10min, and the supernatant was used for measuring
protein concentrations.
2.2. Measurement of Alveolar Fluid Clearance. In the human
lung study, the protein concentrations in aspirated solutions
were measured by Bradford Method. We estimated AFC by
the changes of concentration for bovine serum albumin as
water was absorbed. AFC was calculated by the following
equation: AFC = [(Vi − Vf)/Vi] × 100, where V is the
volume of the instilled bovine serum albumin solution (i)
and the ﬁnal alveolar ﬂuid (f). Vf = Vi × Pi/Pf, where P
represents the protein concentration in the instilled bovine
serum albumin solution (i) and the ﬁnal alveolar ﬂuid (f).
2.3. Cell Culture. A549 cells were obtained from the Amer-
ican Type Culture Collection (ATCC) and grown in
RPMI medium (ATCC) supplemented with 10% fetal
bovine serum, penicillin (100units/mL), and streptomycin
(100μg/mL). Cells were seeded in 75cm2 ﬂasks and incu-
bated in a humidiﬁed atmosphere of 5% CO2, 95% O2 at
37◦C. For patch clamp studies, cells were lifted by 0.25%
trypsin and 0.53mM EDTA (Sigma), then seeded at a
density of 1×106 cells/mL on round coverslips (8mm, WPI)
situated in 24-well culture plates. Cells were grown in the
above medium supplemented with 200nM dexamethasone
to facilitate sodium channel diﬀerentiation, the medium was
replaced every other day.
2.4.PatchClampRecordings. Immediatelybeforeeachexper-
iment, a coverslip bearing A549 cells was removed from the
culture dish and put into a recording chamber, which was
mounted on the stage of an inverted ﬂuorescent microscope
(LeicaDMIRB).Forwhole-cellmodeofpatchclamprecord-
ing, cells were perfused continuously with extracellular ﬂuid
containing (in mM): 140 NaCl, 1.8 CaCl2,1M g C l 2,a n d1 0
HEPES (pH 7.2) [19], following being exposed to ketamine
(30 to 1,000μM) and the Na+ channel blocker amiloride
(10μM), transepithelial transport indicated by amiloride-
sensitive currents were measured. Pipettes were made from
capillary glass electrode with a P-97 micropipette puller
(Sutter). They were back-ﬁlled with internal solution (in
mM): 100 K-gluconate, 40 KCl, 2 MgCl2,0 . 5C a C l 2,2
K2A T P ,4E G T A ,a n d1 0H E P E S( p H7 . 2 )[ 20]. The pipette
resistance varied from 5 to 10MΩ when ﬁlled with this
intracellular ﬂuid. Oﬀset potential was corrected before a
gigaohm seal formation. Series resistance and capacitance
transients were then compensated with an Axopatch 700B
ampliﬁer (Molecular Devices). Currents were digitized with
a Digidata 1440A converter (Molecular Devices), ﬁltered
through an internal four-pole Bessel ﬁlter at 1kHz, and
sampled at 2kHz. Inward and outward whole-cell currents
were elicited by employing a step-pulse protocol from
−120mV to +80mV in 20mV increments every 10s for
500ms duration at a holding potential of −40mV. Steady-
state currents were averaged between 100 and 200ms and
only the cells with stable baseline currents were included in
the results.
2.5. Statistics. Electrophysiological data from patch clamp
studies were primarily analyzed with the Clampﬁt 10.0
(Molecular Devices) software. Furthermore, the measure-
ments were imported into OriginPro 8.0 software (Origin-
Lab) for statistically computation and graphic plotting.
Amiloride-sensitive currents (AS) are deﬁned as the diﬀer-
ence between total current and amiloride-resistant current.
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by ﬁtting the dose-response curve with the Hill equation.
The whole-cell currents among each single A549 cell were
divergent due to various cell size (capacitance), passage, and
culture reagents. Thus the whole-cell channel activity was
presented as amiloride-sensitive whole-cell current density
(ASIdensity, pA/pF) or normalized currents to the one at
−100mV of control group.
For analyses of ex vivo alveolar ﬂuid clearance, the mean
and SE values of amiloride-sensitive AFC fractions were
computed as previously reported [21].
All results are presented as mean ± SEM. One-way
ANOVA computations were used to analyze the diﬀerence of
the means for normally distributed data. Mann-Whitney test
wasappliedfornonparametric data.P<0.05 wasconsidered
as signiﬁcant.
3. Results
3.1. Ketamine Reduces AFC in Human Lungs Ex Vivo. To
examine the potential eﬀects of ketamine on ﬂuid resolution
in distal lung air spaces, we measured AFC in human lung
lobes ex vivo under physiological conditions. The clinical
data of the patients are summarized in Table 1.P u l m o n a r y
function tests were normal in all patients and there were no
signiﬁcant statistic diﬀerences among the four groups.
As shown in Figure 1(a), the normal AFC for 5% bovine
serum albumin control group was 14.4 ± 1.9% (n = 6).
These result consisted with previous observations as well
as our recent publication in normal human lungs [22, 23].
Intratracheal instillation of ketamine (100μM) markedly
decreased the reabsorption of the 5% BSA instillate (10.2 ±
3.6%, P<0.05 versus control, n = 5). We asked the
question of whether ketamine inhibits ENaC activity. To
address this issue, we applied a speciﬁc ENaC inhibitor,
amiloride (1mM). This compound reduced AFC to 6.6 ±
2.8% (P<0.01 versus control, n = 5). Ketamine (keta +
amil) did not further reduce ﬂuid resolution signiﬁcantly
(9.3 ± 3.7%, P>0.05 versus ketamine group, n = 5). Under
these experimental conditions, ketamine can only alter AFC
fractions contributed by non-ENaC pathways. These data
suggest that ketamine could almost completely decrease
amiloride-sensitive fraction of AFC associated with ENaC
(Figure 1(b)).Theseexvivodatademonstratedthatketamine
might decrease transalveolar ﬂuid clearance contributed by
ENaC.
3.2. Ketamine Decreases Amiloride-Sensitive Whole-Cell
Na+ Currents in A549 Cells. Because ketamine decreased
amiloride-sensitive fraction of AFC, we postulated that
ketamine may directly inhibits ENaC activity. We carried out
whole-cell patch clamp studies in A549 cells (a human alveo-
lar epithelial cell line) to further explore the mechanisms for
ketamine-reduced AFC.
Figure 2(a) showed representative recordings of whole-
cell currents in the absence and presence of ketamine, rang-
ing from 0 to 1,000μM in one A549 cell, 10μMa m i l o r i d e
was then added to compute the amiloride-sensitive currents.
Ketamine decreased whole-cell Na+ currents at each holding
potential in a dose-dependent manner. To compute the IC50
value for ketamine, a dose-response curve was plotted with
the amiloride-sensitive currents (ENaC activity) measured
at cell membrane potential of −100mV (Figure 2(b)). The
minimumvalue(0μM)representstheoriginalconcentration
without drug administration and an IC50 value of 63.5 ±
21.7μM for ketamine was calculated when the data were
ﬁtted with the Hill equation. Amiloride-sensitive current
density- (ASIdensity-) voltage curves for average control cur-
rents (control), in the presence of diﬀerent concentrations
of ketamine (30μMt o1 m M )w e r es h o w ni nFigure 2(c).
100∼1000μMketaminecouldinhibittheamiloride-sensitive
Na+ currents signiﬁcantly in patch-clamped A549 cells at
each commanding potential (P<0.05 versus control, n =
7). In contrast, even the maximum dosage of DMSO used
for dissolving amiloride had no obvious eﬀect (data not
shown).
4. Discussion
In this paper, we studied the eﬀects of ketamine on human
alveolar epithelial ﬂuid clearance which has important
clinical signiﬁcance. First, several case reports have shown
that ketamine is a possible reason for lung edema in patients
during intraoperative period [1–3, 5]. If this eﬀect occurred
at the level of the alveolar or distal airway epithelium,
then the threshold for developing alveolar edema could be
downregulated or the resolution of edema, in which active
ion transport plays an important role, might be reduced
by ketamine [8]. In addition, ketamine is widely used for
analgosedation in patients with cardiac and hemodynamic
instability who are liable to the occurrence of lung edema.
In these patients, the decreased of AFC is associated with
increased mortality [12]. Much eﬀort has therefore been
focused on identifying the pathogenic mechanisms under-
lying disturbed AFC in patients and how AFC can be
maintained.
4.1. Ketamine Inhibits Fluid Resolution in Human Lungs.
To investigate whether ketamine inhibited alveolar Na+
transport in the human lung, AFC was measured by a
way of ﬂuid instillation. In this setup, the rate of ex vivo
AFC was signiﬁcantly reduced in human lobes intratra-
cheally administrated ketamine. Addition of amiloride to
the instillate decreased AFC by about 50%, which is in
accordance with previous studies [17, 18, 22, 24]. Previous
studies showed that S-ketamine via iv at clinically relevant
bolus concentrations does not aﬀect AFC in rats [25], the
diﬀerence might result from the many divergent properties
of ENaC between diﬀerent species. For example, cpt-cGMP
activates human but not murine ENaC activity [22]. The
responses to cpt-cAMP are diﬀerent between human and
murine ENaC, too [26]. It is conceivable that ketamine may
reduce ENaC activity in human lungs but may not alter rat
counterpart.
Then whether ketamine acts directly on transepithelial
sodium transport? It is well known that alveolar ﬂuid clear-
ance is majorly determined by amiloride-sensitive sodium
transport pathway [27, 28]. During this study, we applied
ENaC-speciﬁc inhibitor to identify the contribution of4 Journal of Biomedicine and Biotechnology
Table 1: Clinical characteristics of patients.
Control (n = 6) Amiloride (n = 5) Ketamine (n = 5) Keta+am (n = 5)
Age (year) 60.0 ±8.66 4 .8 ±11.46 0 .0 ±8.15 0 .4 ±3.9
Male (%) 50 40 60 80
PaO2(mmHg) 87.4 ±4.58 6 .9 ±6.88 3 .7 ±8.39 0 .2 ±6.0
VC (L) 3.3 ±0.53 .1 ±0.93 .2 ±0.94 .2 ±0.7
FEV1.0 actual value (L) 2.4 ±0.42 .4 ±0.92 .7 ±0.83 .2 ±0.5
FEV1.0 actual/predicted (%) 96.3 ±21.6 108.2 ±10.79 6 .3 ±17.49 7 .3 ±10.4
FVC actual value (L) 3.2 ±0.43 .1 ±0.93 .2 ±0.93 .8 ±0.6
FVC actual/predicted (%) 103.6 ±27.8 113.0 ±24.19 2 .5 ±9.68 7 .5 ±4.8
FEV1.0/FVC (%) 74.6 ±10.37 7 .9 ±7.98 4 .0 ±10.08 3 .9 ±3.8
VC: vital capacity; FEV1.0: forced expiratory volume in 1.0 s; FVC: forced vital capacity. One-way ANOVA.
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Figure 1: Eﬀects of ketamine on alveolar ﬂuid clearance in isolated human lungs. (a) Lungs were treated with 5% bovine serum albumin
dissolved in physiologic saline solution in the absence of drugs (control), in the presence of amiloride (1mM), ketamine (100μM), and both
(Keta + Amil). %AFC60 represents the AFC percentage after 60min. (b) Amiloride-sensitive (AS) AFC. Average AFC values are presented as
the mean ± SEM, one-way ANOVA. ∗P<0.05, ∗∗P<0.01. n = 5-6.
ENaC to the total AFC. Our results showed that ketamine
decreased amiloride-sensitive fraction of AFC, which reﬂects
ENaC activity. Ketamine may regulate potassium channels,
cystic ﬁbrosis transmembrane conductance regulator, Na+-
K+-ATPase, and other transport pathways that coordinately
regulate alveolar ﬂuid balance with ENaC and contribute
to alveolar ﬂuid absorption. However, the evidence is not
available to date. The eﬀects of ketamine on the other
channels mentioned above still await for future studies.
When ketamine was instilled into the lung segments
together with amiloride, no further inhibition eﬀect
occurred. Because the eﬀect of this combination showed
no statistic diﬀerence from the eﬀect of each drug alone,
these ﬁndings demonstrate that ketamine indeed inhibited
the amiloride-sensitive component of AFC, suggesting that
ketamine and amiloride may both act through the same
mechanism, blockade of ENaC competitively. On the other
hand, ketamine may also inhibit accessory Na+ transport
sites that were necessary for the inhibition of amiloride,
which could explain the reason why amiloride did not
induce an additional decrease of alveolar ﬂuid clearance
after administration of ketamine. Ketamine might impair
the airspace ﬂuid balance by disturbing both alveolar ﬂuid
resolution and turnover in human lungs.
4.2. Ketamine Inhibits Alveolar Ion Transport in A549 Cells.
Ketamine inhibited alveolar sodium transport in rat pneu-
mocytes [25] .E N a Ch a sb e e nd o c u m e n t e di nt y p eIa n d
II alveolar cells both physiologically and biochemically. Our
ex vivo data imply that ketamine may eliminate ENaC
activity. To corroborate these observations, we measured
ENaC activity in A549 cells (a human type II alveolar
cell line). We found that ENaC activity was signiﬁcantly
decreased by ketamine in a dose-dependent manner. Our
patch clamp data in A549 cells are in good agreement
with the ex vivo AFC results. The plasma concentration of
ketamine after administration of 2mg/kg intravenously has
been reported to be 1.1×10
−4 M[ 29]. In our study, the same
concentration markedly decreased alveolar AFC in human
lungs and amiloride-sensitive currents in A549 cells. Because
ketamine is cell permeable, the concentration in alveolar
ﬂuid may be close to that in plasma during continuouslyJournal of Biomedicine and Biotechnology 5
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Figure 2: Patch clamp recordings of amiloride-sensitive currents in A549 cells. (a) Representative recordings of amiloride-sensitive current
traces in a cell before (control) and after delivery of diﬀerent concentrations of ketamine (30μM to 1mM) to the bath. (b) Concentration-
dependent inhibition of whole-cell currents by ketamine. For each cell, inward currents recorded at −100mV were measured during
perfusion with external solutions. Amiloride-sensitive (AS) currents were normalized to the current at −100mV of control. IC50 was
calculated by best ﬁtting the raw data points to the Hill equation. Inorm = 1/(1 + (ketamine/IC50))coe. (c) Amiloride-sensitive current
density- (ASIdensity-) voltage curves for average control currents (control), in the presence of diﬀerent concentrations of ketamine (30μMt o
1mM). Average values are presented as the mean ± SEM. One-way ANOVA. ∗P<0.05, n = 7.
intravenous infusion. In addition, ketamine-induced lung
injury may facilitate the leaking of this anesthesiologic
reagent into edematous airspaces. These inhibitory eﬀects of
ketamine on ENaC thus are implicated in clinically reported
lung edema [1–3, 5]. In addition to the direct inhibitory
eﬀects on ENaC, ketamine may cause pulmonary edema by
stimulating nervous system [1, 3] and increasing pulmonary
artery pressure [30].
5. Conclusion
To conclude, our study demonstrated that ketamine can
inhibit ENaC and decrease ENaC-associated ﬂuid clearance
across the distal lung epithelium, which may be the crucial
step of the pathogenesis of ketamine-induced pulmonary
edema.
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